Application of prostaglandin E1 in treatment of patients with chronic renal failure / 中国基层医药

ABSTRACT

Objective To investigate the clinical effects of prostaglandin E1 (PGE1) in the treatment ot chronic renal failure in the 2nd ～ 4th period.Methods 128 patients with CKDs at stage 2 to 4 were selected and randomly divided into the observation group and control group,64 cases in each group.Patients in control group were given routine drug treatment,and patients in observation group were given PGE1 on the basis of the control group.They all treated for 3 months.Renal function indicators before and after treatment,curative effect and adverse reaction were compared.Results There were no statistical differences in renal function indicators before treatment in two groups (t =0.27 ～ 0.95,P ＞ 0.05).After treatment,the 24 hours urinary protein (t =3.41,P ＜ 0.05),creatinine clearance rate (t =4.04,P ＜ 0.05),serum creatinine (t =4.15,P ＜ 0.05),serum urea nitrogen (t =3.92,P ＜ 0.05) between the two groups had statistical differences.Total effective rate of the observation group was 84.37％,which was significantly higher than 57.81％ of the control group (x2 =5.63,P ＜ 0.05).There was no adverse reaction observed in observation group.Conclusion PGE1 might improve patients' proteinuria and renal function in the current situation of lacking effective treatment.